However, sampling bias resulting from intratumoral and intertumoral heterogeneity, as well as the limited amount of tissue available from SCLC patients, may reduce the value of DLL3 as a reliable biomarker for targeted therapy. Here, DLL3 is linked to small cell lung carcinoma.